The HemOnc Pulse
Latest Episodes
Dr. Usmani Highlights Myeloma Presentations from SOHO 2024
On this episode of "The HemOnc Pulse," Saad Usmani, MD, of the Memorial Sloan Kettering Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, to discuss notable presentations on multiple myeloma from the Twelfth Annual Meeting of the Society of Hematologic On
Covering MDS Updates at SOHO 2024 With Dr. Venugopal
On this episode of "The HemOnc Pulse," Chadi Nabhan, MD, MBA, FACP, is joined by Sangeetha Venugopal, MD, of the Sylvester Comprehensive Cancer Center at the University of Miami, to highlight data on myelodysplastic syndromes (MDS) presented at the Twelft
AML News From SOHO 2024 With Dr. Daver
On this episode of "The HemOnc Pulse," Naval Daver, MD, of the MD Anderson Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, to discuss news on acute myeloid leukemia coming out of the Twelfth Annual Meeting of the Society of Hematologic Oncology in Houst
Dr. Shadman Shares SOHO 2024 Data On CLL
On this episode of "The HemOnc Pulse," Mazyar Shadman, MD, MPH, of the Fred Hutchinson Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, to highlight some of the notable presentations on chronic lymphocytic leukemia coming out of the Twelfth Annual Meetin
Dr. Bose on MPN Highlights From SOHO 2024
On this episode of "The HemOnc Pulse," Prithviraj Bose, MD, of the University of Texas MD Anderson Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, to discuss some of the important data on myeloproliferative neoplasms that were presented at the Society o
Part Two: The Question of MRD in CLL Therapy
In part two of this episode, Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Center;Meghan Thompson, MD, of Memorial Sloan Kettering Cancer Center; andAlan Skarbnik, MD, of Novant Health, continue to explore the role of measurable residual disease (M
Dr. Osman on Identifying and Treating High-Risk MDS
On The HemOnc Pulse, Chadi Nabhan, MD, MBA, FACP, met with Afaf Osman, MD, an Assistant Professor at the University of Utah Huntsman Cancer Center, to discuss how high-risk myelodysplastic syndromes (MDS) are distinct from lower-risk classifications and
Dr. Rami Komrokji on Trends in Real-World MDS Care
On The HemOnc Pulse, Chadi Nabhan, MD, MBA, FACP, spoke with Rami Komrokji, MD, Vice Chair of the Malignant Hematology Department at Moffitt Cancer Center in Tampa, Florida, about the state of myelodysplastic syndromes (MDS) care. Moffitt Cancer Center
Part One: The Question of MRD in CLL Therapy
Part one of this episode explores questions in measurable residual disease (MRD) and chronic lymphocytic leukemia (CLL) with Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Center; Meghan Thompson, MD, of Memorial Sloan Kettering Cancer Center; and Ala
‘The HemOnc Pulse’ Live: Unanswered Questions in T-Cell Lymphoma
At the HemOnc Pulse Live meeting in Chicago, an expert panel explores unanswered questions in T-cell lymphoma management. The panelists were Mehdi Hamadani, MD, a Professor of Internal Medicine at the Medical College of Wisconsin, Andrew Evens, DO, MBA,